Cerus (CERS) Total Non-Current Liabilities (2010 - 2026)
Cerus (CERS) posted Total Non-Current Liabilities of $129.3 million for Q2 2026, down 13.37% sequentially from $149.2 million in Q1 2026, and down 15.26% YoY from $152.5 million in Q2 2025.
Cerus (CERS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Cerus has reported Total Non-Current Liabilities for 17 years, with the latest figure at $129.3 million in Q2 2026.
- Quarterly Total Non-Current Liabilities fell 15.26% year-over-year to $129.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $129.3 million (down 15.26% YoY) and the FY2025 annual result came in at $151.5 million, up 8.11% from the prior year.
- Total Non-Current Liabilities retreated to $129.3 million in Q2 2026 per CERS's latest filing, from $149.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $154.0 million in Q3 2023 and troughed at $129.3 million in Q2 2026.
- A 5-year average of $142.3 million and a median of $142.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities advanced 15.92% in 2025, then dropped 15.26% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $146.0 million in 2022, then slipped by 3.4% to $141.1 million in 2023, then fell by 0.66% to $140.1 million in 2024, then gained by 8.11% to $151.5 million in 2025, then fell by 14.68% to $129.3 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $129.3 million, $149.2 million, and $151.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 21.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 40.90 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 42.74 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 2.57 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 3.68 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 23.89 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 9.07 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 3.44 Bn |
| 10 | Cerus | 560.58 Mn | 504.32 Mn | 29.53 Mn | 129.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.25 Mn |
| Mar 31, 2026 | 149.20 Mn |
| Dec 31, 2025 | 151.50 Mn |
| Sep 30, 2025 | 147.76 Mn |
| Jun 30, 2025 | 152.53 Mn |
| Mar 31, 2025 | 146.51 Mn |
| Dec 31, 2024 | 140.13 Mn |
| Sep 30, 2024 | 131.46 Mn |
| Jun 30, 2024 | 131.58 Mn |
| Mar 31, 2024 | 135.54 Mn |
| Dec 31, 2023 | 141.07 Mn |
| Sep 30, 2023 | 153.99 Mn |
| Jun 30, 2023 | 144.37 Mn |
| Mar 31, 2023 | 147.36 Mn |
| Dec 31, 2022 | 146.03 Mn |
| Sep 30, 2022 | 138.08 Mn |
| Jun 30, 2022 | 136.57 Mn |
| Mar 31, 2022 | 138.22 Mn |
| Dec 31, 2021 | 149.54 Mn |
| Sep 30, 2021 | 135.47 Mn |